Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics

被引:37
作者
Daryaee, Fereidoon [1 ]
Tonge, Peter J. [1 ,2 ]
机构
[1] Ctr Adv Study Drug Act, Dept Chem, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Dept Radiol, Stony Brook, NY 11794 USA
基金
美国国家卫生研究院;
关键词
ANAPLASTIC LYMPHOMA KINASE; IN-VIVO; RESIDENCE TIME; INHIBITION; EFFICACY; MORPHINE;
D O I
10.1016/j.cbpa.2019.03.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pharmacokinetic/pharmacodynamic (PK/PD) models predict the effect time course resulting from a drug dose. In this review, we summarize the development of mechanistic PK/PD models that explicitly integrate the kinetics of drug-target interactions into predictions of drug activity. Such mechanistic models are expected to have several advantages over approaches in which concentration and effect are linked using variations of the Hill equation, and where preclinical data are often used as a starting point for modeling drug activity. Instead, explicit use of the full kinetic scheme for drug binding enables time dependent changes in target occupancy to be calculated using the kinetics of drug-target interactions and drug PK, providing a more precise picture of target engagement and drug action in the non-equilibrium environment of the human body. The mechanistic PK/PD models also generate target vulnerability functions that link target occupancy and effect, and inform on the sensitivity of a target to engagement by a drug. Key factors such as the rate of target turnover can also be integrated into the modeling which, together with target vulnerability, provide additional information on the PK profile required to achieve the desired pharmacological effect and on the utility of kinetic selectivity in developing drugs for specific targets.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 39 条
[1]   Gastric acid secretion in the dog:: A mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole [J].
Äbelö, A ;
Holstein, B ;
Eriksson, UG ;
Gabrielsson, J ;
Karlsson, MO .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2002, 29 (04) :365-382
[2]   Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling [J].
Alsadhan, Anfal A. ;
Cheung, Jean ;
Gulrajani, Michael ;
Cook, Erika M. ;
Pittaluga, Stefania ;
Davies-Hill, Theresa ;
Izumi, Raquel ;
Sun, Clare C. ;
Covey, Todd ;
Wiestner, Adrian ;
Herman, Sarah E. M. .
BLOOD, 2018, 132
[3]   Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks [J].
Barf, Tjeerd ;
Kaptein, Allard .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6243-6262
[4]   Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Harrington, Bonnie ;
O'Brien, Susan ;
Jones, Jeffrey A. ;
Schuh, Anna ;
Devereux, Steve ;
Chaves, Jorge ;
Wierda, William G. ;
Awan, Farrukh T. ;
Brown, Jennifer R. ;
Hillmen, Peter ;
Stephens, Deborah M. ;
Ghia, Paolo ;
Barrientos, Jacqueline C. ;
Pagel, John M. ;
Woyach, Jennifer ;
Johnson, Dave ;
Huang, Jane ;
Wang, Xiaolin ;
Kaptein, Allard ;
Lannutti, Brian J. ;
Covey, Todd ;
Fardis, Maria ;
McGreivy, Jesse ;
Hamdy, Ahmed ;
Rothbaum, Wayne ;
Izumi, Raquel ;
Diacovo, Thomas G. ;
Johnson, Amy J. ;
Furman, Richard R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332
[5]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[6]   The drug-target residence time model: a 10-year retrospective [J].
Copeland, Robert A. .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (02) :87-95
[7]   A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy [J].
Daryaee, Fereidoon ;
Zhang, Zhuo ;
Gogarty, Kayla R. ;
Li, Yong ;
Merino, Jonathan ;
Fisher, Stewart L. ;
Tonge, Peter J. .
CHEMICAL SCIENCE, 2017, 8 (05) :3434-3443
[8]   Correlating drug-target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase [J].
Daryaee, Fereidoon ;
Chang, Andrew ;
Schiebel, Johannes ;
Lu, Yang ;
Zhang, Zhuo ;
Kapilashrami, Kanishk ;
Walker, Stephen G. ;
Kisker, Caroline ;
Sotriffer, Christoph A. ;
Fisher, Stewart L. ;
Tonge, Peter J. .
CHEMICAL SCIENCE, 2016, 7 (09) :5945-5954
[9]   Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models [J].
de Witte, Wilhelmus E. A. ;
Rottschafer, Vivi ;
Danhof, Meindert ;
van der Graaf, Piet H. ;
Peletier, Lambertus A. ;
de Lange, Elizabeth C. M. .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (04) :621-635
[10]   Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects [J].
Dolder, Patrick C. ;
Schmid, Yasmin ;
Steuer, Andrea E. ;
Kraemer, Thomas ;
Rentsch, Katharina M. ;
Hammann, Felix ;
Liechti, Matthias E. .
CLINICAL PHARMACOKINETICS, 2017, 56 (10) :1219-1230